Twice-Yearly HIV Shot Shows 100% Effectiveness in Women

Overall reaction

• Many commenters see the twice‑yearly HIV PrEP shot as a major public‑health advance, especially for people who struggle with daily pills or frequent dosing.
• Some frame it as potentially one of the most important public‑health developments of the decade, though others caution that “eradication” is unrealistic and access will be the limiting factor.

Convenience, adherence, and human variability

• Strong debate over whether daily pills are “easy”: some find pill‑taking trivial habit‑forming; others cite travel, chaotic schedules, kids, executive‑function issues, or alcohol use as barriers.
• Several note that real‑world adherence to daily regimens for many conditions is poor, making long‑interval injections more effective in practice.
• A counterpoint: scheduling a shot every 6 months can itself be hard for highly mobile or disorganized people; needle aversion also mentioned.

Existing PrEP options and efficacy

• Current options discussed: generic Truvada, Descovy (daily pills), Apretude (every 2‑month injection).
• One commenter claims Apretude has lower efficacy than pills; another counters that trial data show higher efficacy, linking manufacturer data (possible bias acknowledged).

Cost, access, and policy

• Injectable PrEP in the US/Europe is said to cost >$40k/year list price; tablets are much cheaper.
• Insurance/drug plans in the US often reduce out‑of‑pocket costs substantially; many gay men on tablet PrEP report cost is not a practical barrier.
• For poorer countries, generic access at roughly “a dollar a day” is seen as both a big step forward and still expensive for the poorest.
• Some argue that rich countries should make preventive meds for transmissible diseases free; others highlight the underlying funding/recoupment problem.

Gender, epidemiology, and trial design

• Discussion on why the pivotal study focused on women:
  • In many regions, especially sub‑Saharan Africa, women and girls comprise a large share of people living with HIV and new infections.
  • Preventing infection in women also reduces mother‑to‑child transmission.
  • Designing adequately powered trials for men requires splitting into subgroups (men who have sex with men vs. exclusively with women), complicating study design.
• Others point out regional variation: in the US and similar settings, men are the majority of cases; in South Africa, women have roughly double the incidence.
• One commenter questions African data quality, suggesting possible over‑reporting in women due to aid incentives; others reject that, citing behavioral and societal factors such as lower condom use, polygamy, and past AIDS denialism.

Mechanism and “does it really prevent infection?”

• Commenters highlight that the new drug (a capsid‑targeting agent) is not a vaccine but a long‑acting antiviral, active at multiple stages of the viral lifecycle.
• Some express amazement at a small‑molecule drug remaining effective for six months and wonder about bioaccumulation and long‑term effects (no firm answers in thread).
• One skeptical commenter argues it may not truly prevent infection, only block production of virus from already infected cells, raising concerns about latent infection if treatment stops.
• Others respond that:
  • Standard definitions of PrEP for existing drugs (reverse‑transcriptase and integrase inhibitors) are also about blocking steps in the HIV life cycle.
  • Normal immune function should clear inhibited infected cells; the contrary view is labeled as the “extraordinary” claim, but no direct data are provided either way.
• A further side‑thread debates whether focusing on HIV markers vs. AIDS outcomes is sufficient, and touches on fringe skepticism about HIV as the cause of AIDS; others strongly push back, noting extensive existing evidence and real‑world experience with PrEP.

Behavioral and cultural aspects

• Several gay commenters note that PrEP is widely used in their communities; HIV is perceived more like other STIs given effective prevention and treatment, with increased sexual freedom and less fear.
• One person complains about pervasive pharmaceutical advertising (including for HIV meds) as depressing and intrusive; others note that such ads are unusual outside the US.

Ethics, fairness, and “subscription medicine”

• Some see long‑acting PrEP as emblematic of “subscription medicine” and worry that availability in high‑burden regions depends on corporate decisions.
• Others counter that, given current global IP and healthcare structures, allowing cheap generics in 120+ poorer countries and broad insurance coverage in wealthy ones is close to the best attainable outcome under the status quo.